Close Menu
Advertisement
Subscribe
[the_ad id="32629"]
Acute Lymphoblastic Leukemia

Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL

Editor By No Comments1 Min Read

Jeff Sharman, MD Medical Director of Hematology Research for US Oncology discusses Ibrutinib or Idelalisib Selecting Appropriate Therapy for Relapsed CLL

Share.

Related Posts